Involvement of miRNA polymorphism in mucositis development in childhood acute lymphoblastic leukemia treatment. (27th November 2018)

• Record Type: Journal Article
• Authors: Gutierrez-Camino, Ángela; Umerez, Maitane; Lopez-Lopez, Elixabet; Santos-Zorrozua, Borja; Martin-Guerrero, Idoia; de Andoin, Nagore García; Ana, Sastre; Navajas, Aurora; Astigarraga, Itziar; Garcia-Orad, Africa
• Is Part Of: Pharmacogenomics. Volume 19:Number 18(2018)
• Page Start: 1403
• Page End: 1412
• Publication Date: 2018-11-27
• Subjects: acute lymphoblastic leukemia -- chemotherapy -- miRNA -- mucositis -- SNP; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2018-0113
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: Mucositis, linked to methotrexate, daunorubicin or cyclophosphamide, is a frequent childhood acute lymphoblastic leukemia (ALL) therapy side effect. miRNAs regulate the expression of pharmacokinetic/pharmacodynamic pathway genes. SNPs in miRNAs could affect their levels or function, and affect their pharmacokinetic/pharmacodynamic pathway target genes. Our aim was to determine the association between miRNA genetic variants targeting mucositis-related genes and mucositis-developing risk.Patients & methods: We analyzed 160 SNPs in 179 Spanish children with B-cell precursor ALL homogeneously treated with LAL/SHOP protocols.Results: We identified three SNPs in miR-4268, miR-4751 and miR-3117 associated with mucositis, diarrhea and vomiting, respectively.Conclusion: The effect of these SNPs on genes related to drug pharmacokinetics/pharmacodynamics could explain mucositis, diarrhea and vomiting development during ALL therapy.